Indian pharma

Aurobindo Pharma’s shares closed with a loss of 3.7% as investors feared it may face delays in resolving the issue. Graphic: Naveen Kumar Saini/Mint

US FDA: a risk that keeps on giving

3 min read . 06 Mar 2018
Most companies reported a healthy recovery in domestic sales, as the market situation has turned more normal after the initial disruption caused by GST rollout. Photo: Hemant Mishra/ Mint

Pharma: stable but not improving

1 min read . 02 Mar 2018